📰 Sue Stuart News
Page 2 - Sue Stuart News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sue Stuart. Real-time updates on events, politics, business and more.
January 25, 2021
About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgens differentiating human biology BioBank platform and world-renowned international...
January 6, 2021
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the worlds most respected public health research institutions Abingdon, ...
January 6, 2021
News Category Global Banking & Finance Reviews Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil Bio-Manguinhos, is a wor...
December 18, 2020
Synairgen plc: COVID-19 Clinical Programme Update Phase III trial design adapted which will expedite results Phase III trial to commence dosing in UK imminently Southampton, UK - 18 December 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces updates to the Companys Phase III trial design evaluating SNG001 as a treatment for patients with COVID-19 and positive progress on the regulatory path. Update to Phase III trial (SG018) protocol in COV...
December 17, 2020
Vectura Group plc Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565 Mary-Jane Elliott / Sue Stuart / David Daley About Vectura Vectura is a provider of innovative inhaled drug delivery solutions that enable partners and customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the d...